Table 2.
Characteristics of SBRT treatment for pulmonary sarcoma metastases
| No. (%) | |
|---|---|
| No. of lesions | 95 |
| Location | |
| Ultracentral | 21 (22%) |
| Central | 28 (29%) |
| Peripheral | 46 (48%) |
| Dose/fractionation (BED in Gy) | |
| 30 Gy/5 fractions (48) | 16 (17%) |
| 27 Gy/3 fractions (51.3) | 5 (5%) |
| 35 Gy/5 fractions (59.5) | 5 (5%) |
| 30 Gy/3 fx (60) | 4 (4%) |
| 40 Gy/5 fractions (72) | 9 (9%) |
| 24 Gy/1 fx (81.6) | 1 (1%) |
| 44 Gy/5 fx (82.72) | 1 (1%) |
| 45 Gy/4 fractions (85.5) | 3 (3%) |
| 50 Gy/5 fractions (100) | 32 (32%) |
| 60 Gy/8 fractions (105) | 7 (7%) |
| 48 Gy/4 fractions (105.6) | 5 (5%) |
| 54 Gy/3 fractions (151.2) | 7 (7%) |
| Gross tumor volume | |
| Median (range) | 10.4 (0.2 – 375.8) |
BED: Biologically Effective dose